| Characteristic | MRD Negative N = 1,8481 |
MRD Positive >0.01 N = 5951 |
p-value2 |
|---|---|---|---|
| Demographics | |||
| Social Vulnerability mobility | >0.9 | ||
| Consistently low | 344 (19%) | 109 (18%) | |
| Consistently moderate | 328 (18%) | 98 (16%) | |
| Decreasing | 254 (14%) | 88 (15%) | |
| Increasing | 467 (25%) | 150 (25%) | |
| Consistently high | 455 (25%) | 150 (25%) | |
| Gender | 0.13 | ||
| Female | 824 (45%) | 244 (41%) | |
| Male | 1,024 (55%) | 350 (59%) | |
| Age at diagnosis (years) | <0.001 | ||
| 1-4 | 482 (26%) | 112 (19%) | |
| 5-9 | 772 (42%) | 241 (41%) | |
| 10-14 | 458 (25%) | 182 (31%) | |
| 15-21 | 136 (7.4%) | 60 (10%) | |
| Race/Ethnicity | 0.071 | ||
| Non-Hispanic White | 1,258 (68%) | 401 (67%) | |
| Non-Hispanic Black | 107 (5.8%) | 48 (8.1%) | |
| Hispanic (All races) | 342 (19%) | 114 (19%) | |
| Other | 141 (7.6%) | 32 (5.4%) | |
| Medical insurance provider | 0.13 | ||
| Private | 1,251 (68%) | 399 (67%) | |
| Public | 417 (23%) | 122 (21%) | |
| Other/Unknown | 180 (9.7%) | 74 (12%) | |
| Clinical characteristics | |||
| ALL subtype | <0.001 | ||
| Standard-risk B-cell ALL | 997 (54%) | 226 (38%) | |
| High-risk B-cell ALL | 623 (34%) | 226 (38%) | |
| T-cell ALL | 228 (12%) | 143 (24%) | |
| WBC count at diagnosis | <0.001 | ||
| <50,000/ul | 1,557 (84%) | 436 (73%) | |
| >=50,000/ul | 290 (16%) | 158 (27%) | |
| CNS involvement | 0.5 | ||
| CNS1-2 | 1,804 (98%) | 583 (98%) | |
| CNS3 | 39 (2.1%) | 9 (1.5%) | |
| Cytogenetics | <0.001 | ||
| Favorable | 799 (43%) | 128 (22%) | |
| Neutral | 710 (38%) | 274 (46%) | |
| Unfavorable | 111 (6.0%) | 50 (8.4%) | |
| Missing | 228 (12%) | 143 (24%) | |
| P values: Pearson chi-square (no continuity correction) for categorical variables; Fisher’s exact test for CNS group (sparse counts). Missing data (not shown in table; excluded from p-values per variable): cns_grp=8; wbc_cat=2; sex=1. | |||
| 1 n (%) | |||
| 2 Pearson’s Chi-squared test | |||